Drugs / OSORESNONTRINE
Trials 23
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 118 trials · 1 missed | ||||||
| Phase 1 | NCT04602221 | Dec 2020 → Aug 2022 | — | Boehringer Ingelheim | Completed | Missed primary |
| Phase 1 | NCT03934203 | May → Sep 2019 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03505151 | Apr → May 2018 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03193307 | Jun → Dec 2017 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03151499 | May → Jul 2017 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02853136 | Aug → Oct 2016 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02635750 | Jan → Mar 2016 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02597998 | Sep → Dec 2015 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02438683 | May → Aug 2015 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02392468 | Apr 2015 → Aug 2017 | Alzheimer disease, schizophrenia | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02248259 | Oct 2014 → Jan 2015 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02222168 | Sep → Oct 2014 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01892384 | Jun → Dec 2013 | schizophrenia | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01841112 | Apr → Jul 2013 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01611311 | May → Aug 2012 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01505894 | Jan → Jul 2012 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01493570 | Dec 2011 → Feb 2012 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01343706 | Apr → Aug 2011 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 25 trials · 5 missed | ||||||
| Phase 2 | NCT03351244 | Dec 2017 → Mar 2021 | schizophrenia | Boehringer Ingelheim | Terminated | Missed primary |
| Phase 2 | NCT03230097 | Sep 2017 → Mar 2021 | psychotic disorder | Boehringer Ingelheim | Terminated | Missed primary |
| Phase 2 | NCT02337907 | Jan 2015 → Sep 2017 | Alzheimer disease | Boehringer Ingelheim | Completed | Missed primary |
| Phase 2 | NCT02240693 | Jan 2015 → Sep 2017 | Alzheimer disease | Boehringer Ingelheim | Completed | Missed primary |
| Phase 2 | NCT02281773 | Nov 2014 → May 2016 | schizophrenia | Boehringer Ingelheim | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-02-09 | Boehringer Ingelheim | Results Boehringer Ingelheim refocuses PDE9 inhibition brain research on schizophrenia following results from Phase II Alzheimer's trials prnewswire.com ↗
Boehringer Ingelheim today announced that their Phase II Alzheimer's disease trials with investigational compound BI 409306 had not met their efficacy endpoints and plans for further trials with BI 409306 in AD will therefore not be pursued. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-02-09 | Boehringer Ingelheim | Boehringer Ingelheim refocuses PDE9 inhibition brain research on schizophrenia following results from Phase II Alzheimer's trials prnewswire.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 26 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OSORESNONTRINE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4206492 ↗ |
| Known as | BI 409306 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03934203 ↗ |
| Known as | BI 409306 (C-13/N-15) | “On day 1, subjects were administered the Test treatment (T): a single dose of 50 milligram (mg) of BI 409306 film-coated tablet orally with 240 milliliter (mL) of water,...” NCT03505151 ↗ |
| Known as | Osoresnontrina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4206492 ↗ |
| Known as | SUB 166499 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4206492 ↗ |
| Action | Inhibit | “selective phosphodiesterase 9A (PDE9A) inhibitor” PMID 29177699 ↗ Nov 2017 |
| Modality | Small molecule | “a novel phosphodiesterase type 9 inhibitor” PMID 30755255 ↗ Feb 2019 |
| Route | Oral | “administered orally” NCT01343706 ↗ |
| Target | PDE9A | “selective phosphodiesterase 9A (PDE9A) inhibitor” PMID 29177699 ↗ Nov 2017 |